Previous 10 | Next 10 |
Biopharmaceutical company Chinook Therapeutics (NASDAQ:KDNY) commenced an underwritten public offering of its common stock. In lieu of common stock, the company will also offer and sell to certain investors pre-funded warrants to purchase shares. KDNY intends to grant the underwriters a 30-da...
SEATTLE, May 24, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it has commenced an underwritten public offering of i...
The AFFINITY IgAN cohort of 20 patients is fully enrolled, with 70% of patients in the study having baseline proteinuria over one gram per day despite maximal RAS inhibitor treatment, representing an IgAN patient population at high risk for progression Atrasentan was w...
All patients with IgAN in Cohort 1 have transitioned to subcutaneous (SC) dosing, and BION-1301 remains well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs) BION-1301 continues to demonstrate rapid and sust...
Chinook Therapeutics press release (NASDAQ:KDNY): Q1 GAAP EPS of -$0.54 beats by $0.11. Revenue of $2.7M (+671.4% Y/Y). For further details see: Chinook Therapeutics GAAP EPS of -$0.54 beats by $0.11, revenue of $2.7M
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the fi...
Data on atrasentan to be presented in an oral presentation from the IgA nephropathy (IgAN) patient cohort of the phase 2 AFFINITY basket trial Updated data to be presented from Cohort 1 of Part 3 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Addit...
SEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to present and part...
Chinook Therapeutics (NASDAQ:KDNY) began dosing in a phase 1 trial of CHK-336 in adult healthy volunteers. The company is developing CHK-336 for treating patients with primary hyperoxaluria (PH) and secondary hyperoxaluria due to increased endogenous oxalate production. Hyperoxalurias occurs ...
SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing has been initiated in a phase 1 clinical tri...
News, Short Squeeze, Breakout and More Instantly...
Chinook Therapeutics Inc Com Company Name:
KDNY Stock Symbol:
NASDAQ Market:
Chinook Therapeutics Inc Com Website:
Chinook Therapeutics, Inc. (NASDAQ: KDNY) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 2.86% on the day to $40.3. Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, dev...
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enr...
NEW YORK, NY / ACCESSWIRE / July 27, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sculptor Capital Management Inc. (NYS...